Bronchoplasty is frequently required for radical resection of central typical carcinoid tumours. As sleeve bronchoplasty can be a complex procedure, an accurate evaluation of the tumour location is mandatory. Although the endobronchial part of the tumour can be easily evaluated by bronchoscopy, the exo-bronchial part is difficult to analyse with a standard computed tomography (CT) scan. A three-dimensional (3D) CT scan could be used to identify this exo-bronchial component of the tumour when planning a reconstruction. Herein, we present a case of a 59-year-old woman with a typical central carcinoid tumour of the right main bronchus. After 3D modelling, we successfully performed a total parenchyma-sparing resection with an intermedius bronchus reimplantation into the carina associated with the right upper bronchus anastomosis in the lateral trachea. The follow-up was uneventful. An endoscopy at 3 months showed excellent results.

After tobacco, cannabis is the most widely used drug worldwide, and the move to legalise it is growing in more and more countries. The literature about the involvement of cannabis smoking on the development of lung cancer is scarce and most often reassuring [1][2][3], even though the concentration of carcinogens in cannabis smoke is unquestionably greater than that in tobacco smoke [4]. Moreover, recent studies on cannabis tend to focus on possible therapeutic effects [5]. Studies of the carcinogenic impact of cannabis are indeed limited by its frequent association with tobacco smoking and by its illegal status in most countries [6].Our study aimed to describe the prevalence and study the clinical impact of cannabis use among young patients who underwent surgical resection for primary lung cancer.All patients aged 50 years or less who underwent resection for primary lung cancer in three French University hospitals between 2018 and 2020 were prospectively included in an administrative database and retrospectively reviewed. Patients were stratified into three groups: cannabis and tobacco smokers (CTS), tobacco smokers only (TS) and never smokers (NS).Each patient was contacted by phone: information on demographics, smoking history, recreational drug use, passive smoking exposure, alcohol consumption and family history of malignancy was collected. In case of cannabis and/or tobacco use, patients were asked about starting age, quantity, frequency and duration of use, and the characteristics of smoking. We also retrospectively analysed all medical files to find whether cannabis use was reported. Tumour characteristics (localisation, histology, molecular profile and staging according to the eighth edition of the TNM Classification of Malignant Tumors), surgical plan, post-operative outcomes, presence of emphysema on thoracic computed tomography scan, and oncological follow-up were also collected.All patients gave informed consent to allow medical data prospective collection and retrospective analysis. Data collection was declared to the French National Committee for Informatics and Freedom (CNIL, 2219959). Study protocol was approved by the ethics committee of the French Society of Thoracic and Cardio-vascular Surgery (CERC-SFCTCV, 2020-09-08-02-PRAD).Group comparison for categorical and continuous variables was performed with Fisher's exact (or Chi-square) and Mann-Whitney U-(or Kruskal-Wallis) tests, respectively. Statistical analyses were performed using GraphPad Prism 8.0 (San Diego, CA, USA). p-value <0.05 was considered statistically significant.Between 2018 and 2020, 1329 patients underwent lung resection for primary lung cancer, in all cases nonsmall-cell cancer (NSCLC). Among them, 77 patients were aged 50 years or less and accounted for the study group. 71 patients (92%) answered our phone interview. The data of the remaining six patients were collected through contact with their general practitioner and referent oncologist. 43% (n=33) of patients were cannabis and tobacco users (CTS group), 34% (n=26) were ...

No abstract